FGFR4 and hepatocellular carcinoma: The authors conclude that an effective strategy to suppress HCC metastasis might be using anti-PD-L1 paired with the FGFR4 inhibitor BLU-554 or the MAPK inhibitor trametinib, as ETV4 is a predictive biomarker.